IFITM5 and osteogenesis imperfecta: OI5 (type III/IV OI) showed both high levels of inhibitory regulator DKK1 and osteoclast precursor RANKL and high expression levels of osteoblast and progenitor (SP7, BGLAP) markers well above both non‐OI controls and OI patients.